No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
MDXG240621P10000
- 2.13
- 0.000.00%
15min DelayClose Mar 20 12:58 ET
0.00High0.00Low
0.00Open2.13Pre Close0 Volume0 Open Interest10.00Strike Price0.00Turnover6717.64%IV-17.99%PremiumJun 21, 2024Expiry Date3.33Intrinsic Value100Multiplier-4DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.6677Delta0.0987Gamma3.13Leverage Ratio-29.2280Theta0.0000Rho-2.09Eff Leverage0.0002Vega
Intraday
- 5D
- Daily
News
With 45% Ownership, MiMedx Group, Inc. (NASDAQ:MDXG) Has Piqued the Interest of Institutional Investors
Wound Skin Substitutes Market Global Analysis to 2030, Featuring Coloplast, Smith & Nephew, MTF Biologics, MiMedx, AlloSource, Organogenesis, RTI Surgical, LifeNet Health and Molecular Biologicals
Wound Biologics Market Global Analysis and Forecast to 2030, Featuring Profiles of AlloSource, LifeNet Health, Smith & Nephew, Sanara MedTech, Mtf Biologics, Becton, Dickinson, MiMedx and TissueTech
MiMedx Group, Inc.'s (NASDAQ:MDXG) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
It is hard to get excited after looking at MiMedx Group's (NASDAQ:MDXG) recent performance, when its stock has declined 11% over the past three months. But if you pay close attention, you might gath
Craig-Hallum Maintains MiMedx(MDXG.US) With Buy Rating
Craig-Hallum analyst Chase Knickerbocker maintains $MiMedx(MDXG.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 45.9% and a total average return of 2.1% over the p
MIMEDX to Participate in Upcoming Investor Conferences
MARIETTA, Ga., May 15, 2024 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) ("MIMEDX" or the "Company") today announced that members of its senior management will participate in the following
Comments
Mizuho Boosts MiMedx Group's Price Target to $14, Continues Bullish Outlook.
In a recent move that underscores their confidence in the regenerative medicine sector, Mizuho Securities has maintained its 'Buy' rating on MiMedx Group Inc. (NASDAQ: MDXG) and has raised the price target from a previous estimate to $14. This comes as the company continues to make significant strides in its advanced wound care and surgical tissue solutions. $MiMedx(MDXG.US$
...
In a recent move that underscores their confidence in the regenerative medicine sector, Mizuho Securities has maintained its 'Buy' rating on MiMedx Group Inc. (NASDAQ: MDXG) and has raised the price target from a previous estimate to $14. This comes as the company continues to make significant strides in its advanced wound care and surgical tissue solutions. $MiMedx(MDXG.US$
...
MIMEDX's Chair and CEO have expressed optimism about the new appointments, stating that Olson and Puhy will contribute to the company's strategic vision and provide valuable insights. Their skills and leadership records will elevate the Board.
CFO Doug Rice asserts the new debt facility offers more flexibility for long-term strategic goals. The terms mirror the company's progress in enhancing its financial profile and reducing interest expense.
Analysts say that MiMedx's low projected revenue growth may contribute to its weak P/S ratio. Significant performance improvements would be needed for a potential P/S ratio rise. The low P/S ratio casts doubt on the company's potential despite its share price increase.
1
Carlson's experience could potentially elevate Spectral AI's position in the market. The potential impact of its breakthrough technology could present substantial opportunities for growth and value in the healthcare industry.
Read more